Covid-19 Vaccination in India: On 16 January 2021 India started its national vaccination program against the SARS-CoV-2 virus which has caused the COVID-19 pandemic. The drive prioritizes healthcare workers and frontline workers, and then those over the age of 60, and then those over the age of 45 and suffering from certain comorbidities.
In January 2021 Secretary-General of the United Nations António Guterres said that India's vaccine-production capacity is the best asset the world has. According to health officials, India has administered 13,01,19,310 (130 million) vaccine doses across the country as of 20 April 2021.
Covid-19 Vaccination in India
Covishield:
On 1 January 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca’s COVID-19 vaccine AZD1222 (marketed as Covishield). Covishield is developed by the University of Oxford and its spin-out company, Vaccitech. It’s a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees. It can be stored, transported, and handled at normal refrigerated conditions. It has a shelf-life of at least six months.
Covaxin:
On 2 January 2021, BBV152 (marketed as Covaxin), the first indigenous vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage. However, this approval was met with some concern as the vaccine had not then completed phase-3 trials. On 3 March 2021, Bharat Biotech announced that interim results of Covaxin showed 81% efficacy. The trial was conducted on 25,800 people in India
Sputnik-V
On 12 April 2021, an expert panel approved the Sputnik-V vaccine's emergency use in India. Sputnik-V conducted the phase-III clinical trial in India in September 2020, and the result of the trials showed 91.6% efficacy
Thanks for visiting this useful post, Stay connected with us for more Posts.
